Search research articles
Contact Us
Filters
Showing results (211-220 of 418) with videos related to
Page
of 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J Ratain, Tim Eisen, Walter M Stadler, et al.
Cancer Research
|
March 16, 2026
Editor's Note: Cell Cycle-Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation
John P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Translational Medicine
|
January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Cancer Medicine
|
July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
Benjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Cell
|
March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
Michael P Smith, Holly Brunton, Emily J Rowling, et al.
Oncoimmunology
|
May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
Meghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery
|
February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant Melanomas
Ophélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Science Advances
|
November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
Alvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Page
of 42
Search research articles
Search
Showing results (211-220 of 418) with videos related to
Sort By:
Page
of 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J Ratain, Tim Eisen, Walter M Stadler, et al.
Cancer Research
|
March 16, 2026
Editor's Note: Cell Cycle-Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation
John P Plastaras, Seok-Hyun Kim, Yingqiu Y Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Translational Medicine
|
January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Cancer Medicine
|
July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
Benjamin Izar, William Sharfman, F Stephen Hodi, et al.
Cancer Cell
|
March 16, 2016
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy
Michael P Smith, Holly Brunton, Emily J Rowling, et al.
Oncoimmunology
|
May 4, 2018
A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
Meghan J Mooradian, Alexandre Reuben, Peter A Prieto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Discovery
|
February 3, 2019
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF-, NRAS</i>-, and <i>NF1</i>-Mutant Melanomas
Ophélia Maertens, Ryan Kuzmickas, Haley E Manchester, et al.
Science Advances
|
November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome
Alvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Page
of 42